GE17-0618-05
Protein G Sepharose™ 4 Fast Flow
Cytiva 17-0618-05, pack of 200 mL
Synonyme(s) :
Fast Flow resin, Antibody purification resin, IgG purification resin
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
41106500
Nomenclature NACRES :
NA.56
Produits recommandés
ligand
recombinant protein G lacking albumin-binding region
Conditionnement
pack of 200 mL
Fabricant/nom de marque
Cytiva 17-0618-05
Conditions de stockage
(20% Ehtanol)
Matrice
4% cross-linked agarose
Diamètre moyen
90 μm (d50v)
cleaning in place
2-10
working range
3-9
Adéquation
suitable for bioprocess medium
Température de stockage
2-8°C
Description générale
Protein G Sepharose™ 4 Fast Flow is recombinant protein G coupled to Sepharose™ 4 Fast Flow.
Protein G Sepharose™ 4 Fast Flow has recombinant protein G immobilized by the cyanogen bromide (CNBr) method to Sepharose™ 4 Fast Flow. Protein G exhibit binding specificities that complement Protein A media and binds to the Fc region of IgG from a variety of mammalian species. Protein G Sepharose™ 4 Fast Flow may be used to isolate and purify classes, subclasses and fragments of immunoglobulins from any biological fluid or cell culture medium.
As member of the BioProcess media range, Protein G Sepharose™ 4 Fast Flow meets industrial demands with security of supply and comprehensive technical and regulatory support.
Protein G Sepharose™ 4 Fast Flow has recombinant protein G immobilized by the cyanogen bromide (CNBr) method to Sepharose™ 4 Fast Flow. Protein G exhibit binding specificities that complement Protein A media and binds to the Fc region of IgG from a variety of mammalian species. Protein G Sepharose™ 4 Fast Flow may be used to isolate and purify classes, subclasses and fragments of immunoglobulins from any biological fluid or cell culture medium.
As member of the BioProcess media range, Protein G Sepharose™ 4 Fast Flow meets industrial demands with security of supply and comprehensive technical and regulatory support.
Caractéristiques et avantages
- Binding specificities that complement Protein A media.
- Binds a broad range of IgG species and subclasses.
- Multi-point attachment minimizes ligand leakage.
- Used in a range of research applications.
Stockage et stabilité
Please be aware this product may be shipped 90 days before the expiration date. For more information on the batch specific expiration date, please contact technical service.
Remarque sur l'analyse
To view the Certificate of Analysis for this product, please visit www.cytiva.com.
Informations légales
Sepharose is a trademark of Cytiva
Mention d'avertissement
Warning
Mentions de danger
Conseils de prudence
Code de la classe de stockage
3 - Flammable liquids
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Monique G P van der Wijst et al.
bioRxiv : the preprint server for biology (2021-03-25)
Type I interferon (IFN-I) neutralizing autoantibodies have been found in some critical COVID-19 patients; however, their prevalence and longitudinal dynamics across the disease severity scale, and functional effects on circulating leukocytes remain unknown. Here, in 284 COVID-19 patients, we found
Kanika Vanshylla et al.
Cell host & microbe, 29(6), 917-929 (2021-05-14)
Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the COVID-19 pandemic and informing vaccination strategies. We evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19. Investigating 2,146 samples, we initially detected SARS-CoV-2 antibodies in 94.4%
Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma.
Sara E Vazquez et al.
Journal of clinical immunology, 41(6), 1169-1171 (2021-05-20)
Kanika Vanshylla et al.
Cell host & microbe, 30(1), 69-82 (2022-01-02)
A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-CoV-2 with cross-reactivity to SARS-CoV-1. To uncover their humoral response in detail, we performed single B cell analysis from 10 SARS-CoV-2 elite neutralizers. We isolated and analyzed 126
Monique G P van der Wijst et al.
Science translational medicine, 13(612), eabh2624-eabh2624 (2021-08-26)
Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the prevalence of these antibodies, their longitudinal dynamics across
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique